HCP Live Staff

David Rosmarin, MD, chair of the department of dermatology at Indiana University School of Medicine, joins Raj Chovatiya, MD, PhD, to review recent long-term extension data from the phase 3 TRuE-V clinical program, as well as what is expected next in ruxolitinib cream assessment for vitiligo.

Click here to watch the full video of the live RAD 2023 filming.

Podcasts

Dermatologists Raj Chovatiya, MD, PhD, and David Rosmarin, MD, discuss new research outcomes for the topical JAK inhibitor live from the Revolutionizing Atopic Dermatiti 2023 Annual Meeting in Washington, DC.

The Latest Data for Ruxolitinib Cream in Vitiligo: Finding Context from the Outcomes

Applying New Vitiligo Data & Drugs to Practice

The Latest Data for Ruxolitinib Cream: Finding Context from the Outcomes

Pediatric Vitiligo Management in 2023: What has Changed, and What is to Come

In this live News Network from the Revolutionizing Atopic Dermatitis (RAD) 2023 Annual Meeting in Washington, DC, this month, a trio of dermatologists reflected on the first year of marketed use of ruxolitinib cream (Opzelura) for the treatment of vitiligo in patients aged 12 years and older.

Raj Chovatiya, MD, PhD, assistant professor of dermatology and director of The Center for Eczema and Itch and medical director of clinical trials at the Northwestern University Feinberg School of Medicine in Chicago, IL, discussed the utility of ruxolitinib cream in real-world patients following its historic FDA approval last year, as well as the state of disease monitoring and continued care.

Afterward, he spoke with David Rosmarin, MD, chair of the department of dermatology at Indiana University School of Medicine, to review recent long-term extension data from the phase 3 TRuE-V clinical program, as well as what is expected next in ruxolitinib cream assessment for vitiligo.

Lastly, Chovatiya was joined by Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology for Rady Children's Hospital-San Diego, as well as professor of dermatology and pediatrics and vice-chair of the department of dermatology at UC San Diego School of Medicine, to discuss how ruxolinitib cream altered the management of pediatric and adolescent vitiligo patients ≥12 years old, as well as pediatric-specific considerations for those who may be eligible for JAK inhibitor treatment.

Videos

Managing Vitiligo in 2023: New Therapies, Emerging Data, Pediatric Indications

EP. 1: Schuyler Jones, MD: CAD/PAD: Identifying Risk & Summary of Recent Clinical Trials

EP. 2: Tracy Wang, MD: Extended Thromboprophylaxis: What Do We Know About Scoring, Risk and Contemporary Trials?

EP. 3: Christopher Granger, MD: Atrial Fibrillation: What Have We Learned About NOACs in Special Populations?

EP. 4: Manesh Patel, MD: Putting This All Together: Treatment Pyramid

On June 23, Manesh Patel, MD, Chief of Cardiology and Clinical Pharmacology, Duke University School of Medicine, led the HCPLive® State of the Science Event "Institutional Perspectives in Cardiology: Cardiovascular Risk Management."

Patel was joined by his colleagues at the Duke University School of Medicine, including Schuyler Jones, MD, Tracy Wang, MD, and Christopher Granger, MD, to discuss recent trials, identify risk, and treatment options in the cardiovascular risk management space.  

The conversation surrounded the following topics:

CAD/PAD: Identifying Risk & Summary of Recent Clinical Trials

Extended Thromboprophylaxis: What Do We Know About Scoring, Risk and Contemporary Trials?

Atrial Fibrillation: What Have We Learned About NOACs in Special Populations?

Putting This All Together: Treatment Pyramid

In this series of HCPLive® State of the Science, 4 experts discuss knowledge and treatment in the cardiovascular risk management space. 

Institutional Perspectives: Cardiovascular Risk Management, Chaired By Manesh Patel, MD 

Ryan Ungaro, MD: Managing IBD During COVID-19

Jean-Frederic Colombel, MD, PhD: Early Use of Biologics

Bruce Sands, MD: Emerging Therapies: The Return of Small Molecules

A trio of clinicians recently came together to present data and expertise on a variety of issues related to 

On June 10, Bruce E. Sands, MD, Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology), led the HCPLive® State of the Science Event called Institutional Perspectives in Gastroenterology: Inflammatory Bowel Disease.

Joined by Ryan Ungaro, MD, Assistant Professor of Medicine in the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai and Jean-Frederic Colombel, MD, Director Inflammatory Bowel Disease Center Icahn School of Medicine at Mount Sinai, the trio discussed the following topics:

Emerging Therapies: Newer Biologic Therapies

Emerging Therapies: The Return of Small Molecules

This edition of HCPLive® State of the Science involves 3 experts discussing different trends in IBD treatments and care.

HCP Live Staff

Articles